Skip to main content
Download PDF

Outer packaging labelling of medicines in Southern African Development Community (SADC) countries: comparative analysis of requirements and transition terms for harmonisation

BMC Health Services Research volume 24, Article number: 111 (2024) Cite this article

Abstract

Introduction

The COVID-19 pandemic highlighted an urgent need for harmonised requirements for the regulation of medicines. To fully implement harmonised medicines regulations across Africa, common technical standards of medicine regulations are needed. One such technical standard is the labelling of medicines on outer packaging. In this study, we compared outer packaging labelling requirements and transition terms for harmonization for countries in the Southern African Development Community (SADC) region.

Methods

Data on legislation and/or regulatory guidelines for medicine outer packaging labelling from National Medicines Regulatory Authorities (NMRAs) were obtained for countries in the SADC region (n = 16) by February 2023. A detailed comparative content analysis was conducted to determine alignment with the requirements of the Southern African Development Community (SADC) harmonised labelling guidelines to assess readiness levels of each country to transition to the SADC harmonised labelling guideline for outer packaging of medicines.

Results

Content analysis showed at least 11 out of 16 countries require national legal reform to transition to the SADC harmonised labelling guideline. In all cases where countries specified labelling requirements for outer packaging of medicines, these were stipulated in national medicines legislation.

Conclusion

Even though there is a high level of alignment across the countries in terms of national labelling requirements, most countries in the SADC region would still require national legislative reform to transition to regional harmonised labelling requirements and then ultimately to continental requirements of the African Medicines Agency (AMA).

Peer Review reports

Introduction

Effective regulation of medicines and vaccines is vital for the protection of public health by ensuring adherence to predetermined standards of quality, safety and efficacy. To make this vision of regulatory harmonisation a reality, various regional regulatory harmonisation initiatives were implemented across the continent [1]. Significant progress has been made in implementing collaborative review procedures to circumvent the resource constraints of National Medicines Regulatory Authorities (NMRAs) through the African Medicines Regulatory Harmonisation Initiative (AMRH) and regional joint assessment procedures using reliance models [1,2,3,4,5]. The lack of resources and differences in the time of implementation of recommendations by individual countries have been identified as challenges to the implementation of regulatory harmonisation [6].

The ZAZIBONA program was launched within the Southern African Development Community (SADC) region, in 2013 sought to streamline regulatory review processes through joint assessment procedures and making recommendations for medicines registration, which remains a national process [6,7,8]. To leverage opportunities such as work sharing; it is important to have common technical standards across SADC countries. The alignment of national regulations and standards with the regional harmonised standards will be critical to successful implementation of regulatory harmonisation for medicines, first at a regional economic community (REC) level and then at a continental level through the AMA [1].

A typical example of such technical standards relates to the labelling of medicines on the outer packaging, which not only allows regulators to assess the authenticity of medicines but also patients to correctly identify medicines. to avoid medication errors [9,10,11]. Even though various definitions for ‘label’ or ‘labelling’ can be found both in legislation as well as in published literature, common elements include the following: any brand, written, pictorial or descriptive matter appearing on or attached to a package of a medicine [1, 6, 8, 12,13,14,15,16].

Regulatory requirements for labelling of medicines which companies need to adhere to are either included in national medicines legislation or detailed in technical guidelines [1, 17]. These labelling requirements include information appearing on the outer packaging, immediate packaging and information leaflet contained inside the medicine pack. Labelling requirements for outer packaging of medicines include manufacturing details, distribution details and country specific registration numbers indicating successful registration by an NMRA.

Evidence from several studies that investigated levels of compliance to labelling requirements demonstrated that marketed medicines showed varying levels of compliance, including failure to comply, such as the example from the East Africa Community (EAC), which showed varying levels of compliance even in the presence of harmonised medicine regulations [13, 16, 18]. This is further emphasized by Barton, et al. who cite redundant and non-transparent registration procedures which are widely divergent across countries, including complex country specific labelling requirements and GMP inspections, as problematic for companies to implement. Such complex regulations are reasons why pharmaceutical companies may decide against supplying medicines to specific markets altogether with the resultant impact of higher medicine costs, limited market competition, limited medicine choices which in turn exacerbate public health and social challenges [1, 13, 14, 19].

The SADC guideline on labelling of medicines on outer packaging, titled “Guideline on excipients in the labelling, summary of product characteristics and patient information leaflet of medicinal products for human use “, (hereafter referred to as the SADC Labelling Guideline) seeks to harmonise these requirements across the SADC region and proposes additional requirements which are not currently implemented at SADC country level such as QR coding [20,21,22]. It is hypothesized that the benefits of harmonisation can be achieved at each country level without the need for national legal reform of medicines legislation but rather through implementation of common technical standards for labelling of medicines. This hypothesis was tested using comparative content analysis of medicine labelling requirements in national medicines legislation and technical guidelines in force in SADC member countries [22].

Methods

This study aimed to assess to what degree requirements for the labelling of medicines on outer packaging in all SADC countries, contained in national medicine legislation and technical guidelines, are consistent with the SADC Labelling Guideline through a comparative content analysis of legislation and technical guidelines governing the requirements for labelling of medicines at the national level in SADC countries. The level of change that will be required for individual SADC countries to transition from country specific labelling requirements to implementing the harmonised SADC guidelines was determined.

The 16 countries in the SADC region of Africa are: Angola, Botswana, Comoros, Democratic Republic of Congo, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa, eSwatini, Tanzania, Zambia and Zimbabwe. These countries differ in terms of levels of development, market sizes, income levels and languages (French, Lusophone and Anglophone) and infrastructure [23].

Data collection

For the purposes of this study, medicine labelling requirements were limited to the information printed on the outer packaging of medicines, (Fig. 1), as required by NMRAs in the SADC region, as part of requirements for medicines registration.

Fig. 1
figure 1

Medicine pack illustration with labelling illustration

Full size image

Extensive internet research was conducted to obtain national legislation and/or technical guidelines during February 2023 using multiple search strategies, including NMRA websites, WHO online resources, published literature, pharmaceutical trade association and professional association resources to determine the status of country specific labelling requirements. In addition, to augment the online research and compensate for data gaps, direct engagement with national academics, policymakers and regulators within the researchers’ network was conducted for data verification.

Data analysis

The first step was to determine whether SADC countries have a functioning NMRA and implemented medicines legislation and legal requirements for medicines registration. Legislation was reviewed to determine whether the labelling requirements were included in principal medicines legislation or in technical guidelines.

The SADC labelling guideline was reviewed to identify the specific labelling attributes included [21]. The following attributes were identified: trade name, dosage form, packaging unit size, manufacturer name, batch number, manufacturing date, expiry date, manufacturers’ details, storage information, standard warning, QR code and lastly registration number and scheduling status. Regulatory requirements for outer packaging labelling were reviewed for each SADC country including any country specific requirements, such as scheduling status and registration numbers. These requirements were compared to the SADC guideline, including, to determine how SADC countries would transition to adopting the SADC harmonised guideline.

Results

Our analysis showed that all SADC countries have a NMRA and that 14 out of 16 countries have legal requirements for the registration of medicines with the exception of Lesotho. No data was found for Comoros. These two countries were excluded from further analysis (Fig. 2).

Fig. 2
figure 2

High level analysis of SADC countries labelling requirements

Full size image

Country specific requirements for outer packaging labelling were found in 11 out of 16 SADC countries (69%). Three countries do not require country specific labelling, viz., Democratic Republic of Congo, eSwatini and Madagascar. These countries accept outer packaging labelling from other countries, even though this is not explicitly stated in their respective national regulations.

In all cases where SADC countries specified labelling requirements, (n = 11/16), these were stipulated in national medicines legislation, e.g., the Medicines Acts governing the regulation of medicines and not in technical guidelines. Further detailed analysis of the specific attributes of medicine labelling required on the outer packaging was limited to these 11 countries that were found to have requirements for country specific labelling.

There was consistency in outer packaging labelling attributes across these 11 countries with the exception of Mozambique and Zambia. For these countries deviations were noted in the requirements for the following attributes: recommended dosage, manufacturers name, batch number, manufacturing date and manufacturers details. Madagascar does not require packaging unit size. South Africa requires manufacturers name, batch number, expiry date while manufacturing date and manufacturers details were optional. This is similar to the requirements for Zambia (Table 1). It was further observed that no countries had requirements for QR code printing. However, this is a requirement in the SADC labelling guideline [21, 24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51].

Table 1 Outer packaging labelling requirements for countries with country specific labelling legislation [24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51]
Full size table

Some countries, Botswana, Namibia and Tanzania have requirements for labelling pertaining to specific active ingredients such as paracetamol and/or preservatives as well as non-pharmacological information including reimbursement and pricing information and volume specifications for specific formulation types such as eye drops and ointments (Table 2).

Table 2 Specific technical requirements in medicine legislation for countries which include requirements for outer packaging labelling [24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51].
Full size table

For Francophone and Lusophone countries, Mozambique and DRC, language requirements need to be accommodated. For example, Mozambique required that language requirements be adhered to in terms of information appearing in Portuguese on labelling. No data was found for Angola, Comoros and DRC.

Discussion

The detailed analysis of labelling requirements showed that at least 11 out of 16 countries (69%) will require legal reform at a national level to align their labelling requirements to those of the SADC Labelling guideline final draft dated February 2020.

Labelling requirements stipulated in technical guidelines, i.e., not in medicines legislation, can be updated without the need for legal reform. None of the countries which specified labelling requirements did so in technical guidelines in this study. For the 4 countries which do not currently specify country specific labelling, minor reforms will be required to ensure that the SADC Labelling guideline is implemented and enforced at a national level. For the remaining 8 countries where country specific labelling requirements are contained in national medicines legislation, more significant legal reform will be required to amend this legislation to align with the SADC Labelling guideline. Even though joint assessment procedures have been implemented at a REC level, this does not circumvent the need to adhere to national legislation for medicines registration.

Most significantly, the SADC labelling guideline does not propose any harmonization of requirements for scheduling status and registration numbers which are country specific. Depending on the country’s policymaking processes, this may involve national parliamentary processes which can be lengthy,adding to the complexity of implementation [4]. Although treaties and protocols for medicines regulatory harmonisation exist, such as the AMA Treaty, implementation of agreed regional decisions by countries remains challenging, since treaties are not self-executing, hence requiring domestication of such decisions through national legal reform.

Recommendations for implementation of harmonised labelling for outer packaging of medicines in the SADC region

It is clear from the results of this study that the majority of countries in the SADC region will need to undergo national legal reform of existing medicines legislation to accommodate and/or transition to the harmonised SADC guideline for labelling of medicines. However, there is currently no binding requirement for countries to transition to harmonised regulatory processes while national medicines legislation remains enforced. In parallel, at an African continent level, there has been an increased focus and momentum on the establishment of African Medicines Agency (AMA) which will further promote the development and adoption of harmonised regulatory policies and standards for the regulation of medical products across the African continent [52]. momentum should be leveraged to develop operational plans at a country level to implement harmonised medicine regulatory policies such as those related to labelling requirements for outer packaging of medicines.

Limitations to the study

Information regarding labelling requirements for each of the countries was challenging to find through online resources as not all the NMRAs have comprehensive, up-to-date online resource portals or websites. In some cases, information was obtained through email contact with key policy officials, academics in-country and professional organisations of healthcare professionals such as pharmacists. In some cases, information provided could not be verified through relevant documentation.

Legislative information differed in phrasing and needed to be interpreted for purposes of standardisation for the analysis. Sigonda et al., claimed that all African countries have a functioning regulatory authority. In this study, we were not able to confirm this using the various methods described. Finally, legislation, such as that from Angola, is published in Portuguese and therefore needed to be translated since the authors are mainly English-speaking.

Conclusion

The majority of SADC countries currently have country specific regulatory requirements for outer packaging labelling of medicines which are legislated The SADC Labelling Guideline aims to harmonise these labelling requirements across the SADC region. Further strengthening of the operationalisation of the AMA could assist in increasing the momentum of harmonisation by creating a pathway for countries to transition to harmonised regulatory requirements. Further research is recommended to investigate the impact on NMRAs and pharmaceutical companies in the implementation of harmonised regulatory requirements in the absence of binding legal frameworks at a regional and continental level.

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. All data generated or analysed during this study are included in this published article.

References

  1. Miletic N, Adam S, Acquah J, Aziz Z, Joos A, Mwangi JM. What makes Joint Assessment procedures (JAPs) attractive to the innovative industry: successes, challenges, and proposed improvements. Front Med;10:1207954.

  2. World Health Organization. Assessment of medicines regulatory systems in sub-Saharan African countries: an overview of findings from 26 assessment reports. WHO.(Updated 2010.Accessed 11. February 2014.) Available from http://apps.who.int/medicinedocs/en/d/Js17577en 2010.

  3. PATH. Implementing the African Union Model Law at the Regional and National Level. 2016; Available at: https://www.path.org/resources/implementing-the-african-union-model-law-at-the-regional-and-national-level/. Accessed 10 Jan, 2023.

  4. Ndomondo-Sigonda M, Miot J, Naidoo S, Ambali A, Dodoo A, Mkandawire H. The African Medicines Regulatory Harmonization Initiative: progress to date. Med Res Archives 2018;6(2).

  5. Ndomondo-Sigonda M, Ambali A. The African medicines regulatory harmonization initiative: rationale and benefits. Clin Pharmacol Ther. 2011;89(2):176–8.

    Article  CAS  PubMed  Google Scholar 

  6. Sithole T, Mahlangu G, Walker S, Salek S. Regulatory authority evaluation of the effectiveness and efficiency of the ZaZiBoNa collaborative medicines registration initiative: the way forward. Frontiers in medicine 2022;9.

  7. Sithole T, Mahlangu G, Salek S, Walker S. Evaluating the success of ZaZiBoNa, the southern African development community collaborative medicines registration initiative. Therapeutic Innov Regul Sci. 2020;54(6):1319–29.

    Article  Google Scholar 

  8. Sithole T, Mahlangu G, Walker S, Salek S. Pharmaceutical industry evaluation of the effectiveness and efficiency of the ZaZiBoNa collaborative medicines registration initiative: the way forward. Front Med. 2022;9:898725.

    Article  Google Scholar 

  9. Kenagy JW, Stein GC. Naming, labeling, and packaging of pharmaceuticals. Am J Health-System Pharm. 2001;58(21):2033–41.

    Article  CAS  Google Scholar 

  10. Jeetu G, Girish T. Prescription drug labeling medication errors: a big deal for pharmacists. J Young Pharmacists. 2010;2(1):107–11.

    Article  CAS  Google Scholar 

  11. Poudel RS, Shrestha S, Thapa S, Poudel BK, Chhetri M. Assessment of primary labeling of medicines manufactured by Nepalese pharmaceutical industries. J Pharm Policy Pract. 2018;11(1):13.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Narsai K, Williams A, Mantel-Teeuwisse AK. Impact of regulatory requirements on medicine registration in African countries - perceptions and experiences of pharmaceutical companies in South Africa. South Med Rev. 2012;5(1):31–7.

    PubMed  PubMed Central  Google Scholar 

  13. Sillo HB, Masota NE, Kisoma S, Rago L, Mgoyela V, Kaale EA. Conformity of package inserts information to regulatory requirements among selected branded and generic medicinal products circulating on the east African market. PLoS ONE. 2018;13(5):e0197490.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Sillo HB. Comparison of medicines legislation in the East African Community. WHO Drug Information. 2016;30(4):567.

    Google Scholar 

  15. Guchelaar H, Kalmeijer MD, Jansen ME. Medication error due to ambiguous labelling of a commercial product. Pharm World Sci. 2004;26(1):10–1.

    Article  PubMed  Google Scholar 

  16. Athuraliya N, Walkom EJ, Dharmaratne S, Robertson J. Assessing medication packaging and labelling appropriateness in Sri Lanka. J Pharm Policy Pract. 2016;9(1):38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Narsai K, Williams A, Mantel-Teeuwisse AK. Impact of regulatory requirements on medicine registration in African countries–perceptions and experiences of pharmaceutical companies in South Africa. South med Rev. 2012;5(1):31.

    PubMed  PubMed Central  Google Scholar 

  18. Guchelaar H, Colen HB, Kalmeijer MD, Hudson PT, Teepe-Twiss IM. Medication Errors Drugs. 2005;65(13):1735–46.

    PubMed  Google Scholar 

  19. Barton I, Avanceña AL, Gounden N, Anupindi R. Unintended consequences and hidden obstacles in medicine access in Sub-saharan Africa. Front Public Health. 2019;7:342.

    Article  PubMed  PubMed Central  Google Scholar 

  20. African Medicines Regulatory Harmonization Initiative A. SADC Concludes Draft Guideline to Harmonise Product Information and Labelling Requirements. 2019; Available at: https://www.nepad.org/publication/african-medicines-regulatory-harmonisation-programme-q4-2019-newsletter. Accessed 23/09/, 2020.

  21. SADC Secretariat. Guideline on excipients in the labelling, summary of product characteristics and patient information leaflet of medicinal products for human use. 2020; available at: www.sahpra.org.za. Accessed 6 Feb, 2023.

  22. SADC Secretariat. SADC Guideline on product information. 2018; Available at: https://www.sahpra.org.za/wp-content/uploads/2020/01/e327093bDRAFTSADCGUIDELINEONPRODUCTINFORMATION_LABELLING_version4_26Jun20191.pdf. Accessed 16th February, 2023.

  23. World Bank. World Bank Group country classifications by income level for FY24 (July 1, 2023- June 30, 2024). 2023; Available at: https://blogs.worldbank.org/opendata/new-world-bank-group-country-classifications-income-level-fy24. Accessed Dec 4, 2023.

  24. Orgao Oficial da Republica de Angola. Decreto Presidencial 315.20 Regulamento registo medicamentos. 2020; Available at: https://armed.gov.ao/wp-content/uploads/2021/12/Decreto-Presidencial-315.20-Regulamento-registo-medicamentos.pdf. Accessed Feb, 2023.

  25. Botswana Drugs Advisory Board. Guidelines on Drug Registration Applications in Botswana. 2000; Available at: https://www.moh.gov.bw/Publications/registration%20guidelines.pdf. Accessed Dec, 2021.

  26. Ministry of Health and Wellness Botswana. MRSA 2019 Regulations Botswana. 2019; Available at: https://www.bomra.co.bw/index.php/bomra-downloads/publications/category/31-regulations. Accessed Dec, 2021.

  27. Ministry of Health and Wellness, Medicines B. and Related Substances Act 2013 Botswana. 2013; Available at: https://www.bomra.co.bw/index.php/bomra-downloads/publications/category/19-mrs-act. Accessed Dec, 2021.

  28. Malawi Ministry of Health. Pharmacy Medicines and Poisons Regulations Arrangement of Regulations Malawi. 1998; Available at: http://www.rrfa.co.za/wp-content/uploads/2012/11/Pharmacy-Medicines-and-Poisons-Regulations-Arrangement-of-Regulations-Malawi-9808.pdf. Accessed Nov, 2022.

  29. Malawi Ministry of Health. Malawi Pharmacy, Medicines and Poisons Act., 1988 (No. 15 of 1988). 1988; Available at: https://leap.unep.org/countries/mw/national-legislation/pharmacy-medicines-and-poisons-act-1988-no-15-1988. Accessed Apr 24, 2023.

  30. Ministerio da Sauda M. Mozambique: Data for Complete registration. 1999; Available at: http://www.misau.gov.mz/index.php/decretos. Accessed June, 2022.

  31. Ministerio da Sauda M. Mozambique Decreto 22 99 de 4 de maio regulamento do sistema do registo do medicamento. 1999; Available at: http://www.misau.gov.mz/index.php/decretos. Accessed June, 2022.

  32. Namibia Ministry of Health & Social Services. Medicines and Related Substances Control Act 13 of 2003. 2020; Available at: https://laws.parliament.na/annotated-laws-regulations/law-regulation.php?id=146. Accessed Oct, 2022.

  33. Namibia Ministry of Health & Social Services. General Regulations to the Medicines and Related Substances Control Act 13 of 2003. 2020; Available at: https://laws.parliament.na/annotated-laws-regulations/law-regulation.php?id=146.

  34. South African Health Products Regulatory Authority. Guidance for the submission of the South African CTD /eCTD -General & Module 1. 2019; Available at: https://www.sahpra.org.za/product-registration-process/. Accessed 23 June, 2020.

  35. Ministry of Health SA. Medicines and Related Substances Act, No. 101 of 1965. 2017; Available at: www.greengazette.co.za. Accessed 23 June, 2020.

  36. Seychelles Ministry of Health & Social Development. Republic of Seychelles, Seychelles National Medicine Policy., 2009; Available at: file:///C:/Users/knars/Downloads/SEYCHELLES%20NATIONAL%20MEDICINE%20POLICY.pdf. Accessed Jan, 2023.

  37. Republic of Seychelles. Medical products and Pharmacy Operations Bill. 2022; Available at: http://www.health.gov.sc/index.php/policies/. Accessed Feb, 2023.

  38. Department of Health RoS. Seychelles National Health Policy. 2017; Available at: http://www.health.gov.sc/wp-content/uploads/National-Health-Policy_final-26062015.pdfs/0. Accessed Jan, 2023.

  39. Tanzania Food and Drugs Authority. Guidelines on Format and Content of Labels for Medicinal Products. 2015; Available at: https://www.tmda.go.tz/publications/42?page=2. Accessed 6th April, 2020.

  40. Tanzania Food and Drugs Authority. Guidelines on Submission of Documentation for Registration of Human Pharmaceutical Products. 2015; Available at: https://www.tmda.go.tz/publications/42?page=1, 2020.

  41. Ministry of Health Zambia. General guidelines for submitting applications for registration of a medicine. 2016; Available at: http://www.who.int/medicines/areas/coordination/zambia_guidelines_registrationc.pdf. Accessed 20 March, 2023.

  42. Zambia Ministry of Health. The Medicines and Allied Substances Act. 2013. 2013; Available at: http://www.rrfa.co.za/wp-content/uploads/2012/11/The-Medicine-and-Allied-Substances-Act-2013.pdf. Accessed 10 Oct, 2020.

  43. Zambia Ministry of Health. The Pharmaceutical Act 2004. 2004; Available at: http://www.rrfa.co.za/wp-content/uploads/2012/11/The-Pharmaceutical-Act-20041.pdf. Accessed 10 Oct, 2020.

  44. Government of Zambia. The Medicines and Allied Substances Act. 2019; Available at: http://www.zamra.co.zm/wp-content/uploads/2019/12/S.-I.-No.-79-of-2019The-Medicines-and-allied-Substance-Marketing-Authorisation-of-Medicines-Regulations.pdf. Accessed 10 Oct, 2020.

  45. Medicine Control Authority Zimbabwe. Guideline on submission of documentation for registration of a multisource (generic) finished pharmaceutical product (FPP): Quality part in the CTD format. 2013; Available at: http://www.mcaz.co.zw/index.php/downloads/file/74-mcaz-ctd-guidelines. Accessed 8th April, 2020.

  46. Medicine Control Authority of Zimbabwe. Guidelines on the import and export of registered medicines - Zimbabwe. 2017; available at: www.mcaz.co.zw. Accessed April, 2020.

  47. Zimbabwe Ministry of Health. Medicines and, Act ASC. 2015. 2015; Available at: http://extwprlegs1.fao.org/docs/pdf/zim24977.pdf. Accessed Oct, 2020.

  48. Zimbabwe Ministry of Health. Medicines and Allied Substances Control General Regulations. 1991; Available at: https://www.mcaz.co.zw/index.php/downloads/category/7-regulations?download=99:medicines-and-allied-substances-control-general-regulations-1991-si-150-of-1991&start=10. Accessed 5 Dec, 2022.

  49. Mauritius Pharmacy Board. Mauritius application for registration of a drug. 2012; Available at: http://www.rrfa.co.za/mauritius/guidelines/. Accessed June, 2022.

  50. Mauritius Ministry of Health and Quality of Life. Procedures for the registration, renewal, change in characteristics and extension in range of both imported and locally manufactured registered pharmaceutical products. 2016; Available at: http://health.govmu.org/English/Legislations/Documents/Pharmaceutical%20products%20(fees)/Procedures%20Guidelines%20%20for%20the%20registration%20of%20pharmaceutical%20%20products.pdf.

  51. Mauritius Ministry of Health and Wellness. The Pharmacy Council Act, Act No. 13 of 2015. 2015; Available at: http://health.govmu.org/English/Legislations/Pages/Pharmacy%20Act%202015.pdf. Accessed Oct, 2022.

  52. Cullinan K. African Union is Making ‘Good Progress’ in Setting up its Medicines Agency. 2023; Available at: https://healthpolicy-watch.news/african-union-is-making-good-progress-in-setting-up-its-medicines-agency/. Accessed 13 March, 2023.

Download references

Acknowledgements

Regulators in the SADC region are acknowledged for their information and input.

Funding

No funding was received for this study.

Author information

Authors and Affiliations

  1. Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands

    K. Narsai, H. G.M Leufkens & A. K. Mantel-Teeuwisse

  2. Nelson Mandela School of Public Governance, Cape Town, South Africa

    K. Narsai

  3. Medicines Control Authority of Zimbabwe (MCAZ), Harare, Zimbabwe

    F. B. Masekela

Authors
  1. K. Narsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. B. Masekela
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. G.M Leufkens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. K. Mantel-Teeuwisse
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Kirti Narsai: study conceptualization, data analysis, initial draft of manuscriptFarai B Masekela: policy verification, stakeholder engagement with regulators in SADC countries, data analysis, input into manuscriptHubert GM Leufkens: supervision, manuscript review and editingAukje K Mantel-Teeuwisse: study conceptualization, data interpretation, manuscript review and editing.

Corresponding author

Correspondence to A. K. Mantel-Teeuwisse.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Authors have declared that there are no competing interests applicable to this study

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Narsai, K., Masekela, F.B., Leufkens, H.G. et al. Outer packaging labelling of medicines in Southern African Development Community (SADC) countries: comparative analysis of requirements and transition terms for harmonisation. BMC Health Serv Res 24, 111 (2024). https://doi.org/10.1186/s12913-024-10585-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12913-024-10585-0

Keywords

BMC Health Services Research

ISSN: 1472-6963

Contact us